Life AI Net
홈
아카이브
계산기
디렉토리
뉴스레터
Hot
로그인
한국어
English
简体中文
Deutsch
Français
Español
日本語
한국어
العربية
Auto
홈
아카이브
계산기
디렉토리
뉴스레터
English
简体中文
Deutsch
Français
Español
日本語
한국어
العربية
Auto
로그인
홈
아카이브
계산기
디렉토리
More
실시간
Lonza News
Is Lonza Group (SWX:LONN) Pricing Too High After Recent Share Price Swings? - Yahoo Finance
Thermo Fisher
TMO Thermo Fisher Scientific Inc falls 2.95 percent post Q4 2025 earnings despite narrow EPS beat and 3.9 percent year-over-year revenue growth. - Investment Community Signals - UBND thành phố Hải Phòng
FierceBiotech
Lilly reneges on remainder of Rigel deal in another blow for RIPK1 inhibitors
Thermo Fisher
Thermo Fisher (TMO) Q4 2024 Earnings Transcript - AOL.com
Waters
WAT (Waters Corporation) rises 1.06 percent after Q4 2025 results, as 7 percent revenue growth offsets minor EPS miss. - Earnings Risk - Cổng thông tin điện tử Tỉnh Sơn La
FierceBiotech
McKesson swaps minority stake in surgical unit to Apollo Funds for $1.25B
FierceBiotech
AcuityMD raises $80M to help bolster AI in the medtech industry
FierceBiotech
AACR: NCI leader Letai battles ‘misinformation’ to assure anxious researchers that ‘funding is strong’
FierceBiotech
Merck goes with Google for AI push, striking enterprise partnership worth up to $1B
BioWorld
Appointments and advancements for April 22, 2026
BioWorld
Financings for April 22, 2026
BioWorld
In the clinic for April 22, 2026
Lonza News
Is Lonza Group (SWX:LONN) Pricing Too High After Recent Share Price Swings? - Yahoo Finance
Thermo Fisher
TMO Thermo Fisher Scientific Inc falls 2.95 percent post Q4 2025 earnings despite narrow EPS beat and 3.9 percent year-over-year revenue growth. - Investment Community Signals - UBND thành phố Hải Phòng
FierceBiotech
Lilly reneges on remainder of Rigel deal in another blow for RIPK1 inhibitors
Thermo Fisher
Thermo Fisher (TMO) Q4 2024 Earnings Transcript - AOL.com
Waters
WAT (Waters Corporation) rises 1.06 percent after Q4 2025 results, as 7 percent revenue growth offsets minor EPS miss. - Earnings Risk - Cổng thông tin điện tử Tỉnh Sơn La
FierceBiotech
McKesson swaps minority stake in surgical unit to Apollo Funds for $1.25B
FierceBiotech
AcuityMD raises $80M to help bolster AI in the medtech industry
FierceBiotech
AACR: NCI leader Letai battles ‘misinformation’ to assure anxious researchers that ‘funding is strong’
FierceBiotech
Merck goes with Google for AI push, striking enterprise partnership worth up to $1B
BioWorld
Appointments and advancements for April 22, 2026
BioWorld
Financings for April 22, 2026
BioWorld
In the clinic for April 22, 2026
아카이브
검색
검색
최신
오래된 순
지우기
@BioWorld
전체
1071
출처
BioWorld
검색어
--
BioWorld
2026년 2월 4일
Regulatory actions for Feb. 4, 2026
BioWorld
2026년 2월 4일
BARDA offers $100M in prize money for antiviral development
BioWorld
2026년 2월 4일
First-in-class fusion protein reverses T-cell exhaustion across multiple models
BioWorld
2026년 2월 4일
STK-026: a next-generation IL-12 therapy with improved safety profile
BioWorld
2026년 2월 4일
TGR5 as a target for acute kidney injury
BioWorld
2026년 2월 4일
A humanized mouse mimics Fcγ receptor biology in antibody essays
BioWorld
2026년 2월 4일
Kinoteck Therapeutics synthesizes WRN inhibitors for cancer
BioWorld
2026년 2월 3일
Regulatory actions for Feb. 3, 2026
BioWorld
2026년 2월 3일
Switching off resistance: Lixa’s bold AMR bet
BioWorld
2026년 2월 3일
Why many global drugs never reach Japan
BioWorld
2026년 2월 3일
China NMPA approves Sciwind’s GLP-1 injection for diabetes
BioWorld
2026년 2월 3일
Elevar gets new CEO, files NDAs for lirafugratinib, rivoceranib
BioWorld
2026년 2월 3일
Amgen quits Kyowa Kirin deal, returns rocatinlimab
BioWorld
2026년 2월 2일
In the clinic for Feb. 2, 2026
BioWorld
2026년 2월 2일
Other news to note for Feb. 2, 2026
BioWorld
2026년 2월 2일
Regulatory actions for Feb. 2, 2026
BioWorld
2026년 2월 2일
Money raised by biopharma
BioWorld
2026년 2월 2일
Biopharma money raised: Jan. 1-30, 2026
이전
32 / 60
다음